Search News

Archive Crawler
India Asia Middle East Australasia Europe N.America S.America Africa
PR Newswire
Business Wire India
Globe Newswire
BizWire Express

Google Custom Search
Click here for Free Industry Resources!
Artificial Life to Launch 'GluCoMo'

                First Major Telemedicine Mobile App

LOS ANGELES and HONG KONG, June 30, 2010 (GLOBE NEWSWIRE) -- Artificial
Life, Inc., (OTCBB:ALIF) (, a leading
provider of award-winning mobile 3G technology and applications,
announced today their soon to be launched mobile telemedicine health
solution GluCoMo (short for: GluCose Monitor), the first in a series of
planned mobile healthcare products.

GluCoMo is a diabetes management solution leveraging Artificial Life's
OPUS-M(TM) platform for end-consumers, healthcare providers and
healthcare businesses. GluCoMo is scheduled for commercial availability
in July, 2010.

Introducing GluCoMo

The application is a mobile telemedicine and healthcare solution
allowing diabetics, caregivers, doctors, and hospitals to share and
communicate through mobile mediums such as smartphones, tablets,
netbooks and other mobile internet devices. With the facilitation of
mobile data sharing and smart back-end processes, the goals are to
promote better personal diabetes management habits, increase peace of
mind for friends, families and caregivers, and enable remote and real
time monitoring and management of patients by doctors and hospitals for
advancement in healthcare services and a reduction in administration

GluCoMo is a customized mobile device front-end client and portal as
well as a custom back-end infrastructure supported by Artificial Life's
m-commerce solution OPUS-M:


The GluCoMo front-end is comprised of two parts, a mobile client and
web portal. The mobile client is able to support most major smartphone
platforms allowing users to keep track of relevant information in real
time such as blood sugar levels, calorie intake, personal activities,
medication intake and more. Visualization of the data gives users quick
snapshots of their medical history. Sharing of information is also
simplified and promoted through online social communities and forums so
that users can quickly share their latest medical status, diabetic
activities and medical information with others. For greater flexibility
and convenience, a synchronized web portal is also available for users,
their friends, family members and caregivers.


The GluCoMo back-end is powered by Artificial Life's OPUS-M technology
and allows for friends, families, and caregivers to share critical
information and thoughts with each other.

Business Model

The front-end mobile client of GluCoMo will initially be launched as a
limited free mobile app and service. Depending on the needs of the
users, additional features and functions for the mobile client can then
be purchased inside the mobile app in the coming versions.

GluCoMo will soon also be offered as a white label solution and can be
adopted by doctors, health clinics, hospitals and/or healthcare
industry businesses. The pricing of the customization, integration and
maintenance services are based on monthly rental and usage fees.

"Artificial Life further expands its business app portfolio by
launching a first and powerful mobile medical solution for diabetics.
Other telemedicine products will follow," said Eberhard Schoneburg, CEO
of Artificial Life, Inc.

About Artificial Life, Inc.

Artificial Life, Inc. has been a pioneer in artificial intelligence and
mobile technology since its inception in Boston in 1994. We are a
public US corporation (OTCBB:ALIF) with listing on the Frankfurt Stock
Exchange (Frankfurt:AIF) (XETRA:AIF) and headquarters in Hong Kong. Our
production center is in Hong Kong and we have additional offices in
Berlin, Germany (EMEA headquarters), Los Angeles and Tokyo, Japan. As a
leading provider of broadband mobile content and technology solutions
in the world, we develop and sell a wide range of mobile games and
applications for 3G, 3.5G and 4G network-enabled mobile (smart) phones.

The Artificial Life logo is available at

For more information about Artificial Life, Inc., please visit our
website or our product websites:,, and





Forward-Looking Statements:

This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
forward-looking statements include, without limitation, statements
regarding our future results of operations, financial condition and
business prospects. In some cases, you can identify forward-looking
statements by terminology such as "may", "will", "should", "expect",
"intend", "plan", "anticipate", "believe", "estimate", "predict",
"potential", "continue" or the negative of these terms or other
comparable terminology. Although such statements are based on our own
information and information from other sources we believe to be
reliable, you should not place undue reliance on them. These statements
involve risks and uncertainties, and actual market trends or our actual
results of operations, financial condition or business prospects may
differ materially from those expressed or implied in these forward
looking statements for a variety of reasons. Potential risks and
uncertainties include, but are not limited to, our ability to obtain
additional funding to operate and grow our business; the unproven
potential of our mobile gaming business model; changing consumer
preferences and uncertainty of market acceptance of our products;
timely adoption and availability of 3G mobile technology; market
acceptance for use of mobile handheld devices to play the interactive
games; unpredictable mobile game development schedules; our reliance on
a relatively small number of brands; our ability to license brands from
others; our dependence upon resellers and telecommunication carriers
and operators to distribute our products; our ability to successfully
develop, introduce, and sell new or enhanced products in a timely
manner; and the timing of new product announcements or introductions by
us or by our competitors. For additional discussion of these risks and
uncertainties and other factors, please see the documents we file from
time to time with the Securities and Exchange Commission, including our
Annual Report on Form 10-KSB filed on March 16, 2010. We assume no
obligation to update any forward-looking statements, which apply only
as of the date of this press release.

CONTACT:  Artificial Life
          IR and PR Contact: 
          Adeline Law
          (+852) 3102 2800